Cangrelor: Additional Research Findings Not Translating into Clinical Practice

The potent and fast endovenous platelet inhibition provided by Cangrelor reduces ischemic events early in the course of acute coronary syndrome. However, and despite mounting evidence, the drug is not reaching the clinical practice.  

COMPASS: un nuevo lugar para el rivaroxaban en cardiopatía isquémica crónica

This is a sub-analysis of the CHAMPION PHOENIX, which sought the timing, number and type of early events that could be prevented within 2 hours of randomization by using cangrelor (as sole P2Y12 endovenous inhibitor) vs clopidogrel.

Most ischemic events observed in the study (63%) occurred within 2 hours after randomization, being repeat MI the most common, followed by stent thrombosis, ischemia driven revascularization, and death. 

Cangrelor significantly reduced the combined primary end point vs clopidogrel (4.1% vs 5.4%; HR, 0.76 CI 95%, 0.64 to 0.90; p=0.002). Additionally, it cut down the chance of acute stent thrombosis by nearly half within 2 hours of cangrelor administration (0.9% versus 1.6%; HR 0.57 CI 95%, 0.40 to 0.80; p=0.001).

All these advantages of the potent and faster cangrelor (thanks to its endovenous delivery) disappear if analyzed between 2 and 48 hours after randomization


Read also: Clnical Practice Dissociated from Study Outcomes: Bad News for Our Patients?


The benefits of the only endovenous P2Y12 inhibitor can only be found within the two first hours. This might be the reason why it has not been adopted in the cath lab, despite favorable data. 

Moderate or severe bleeding events were rare and saw no differences between branches. 

Conclusion

The reduction of ischemic events and general efficacy of cangrelor happen fairly early and during the time when patients are being actively treated with the drug. Event curves level off 2 hours after randomization vs. clopidogrel. 

CIRCINTERVENTIONS-120-010390

Original title: Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.

Reference: Matthew A. Cavender et al. Circ Cardiovasc Interv. 2022 Jan;15(1):e010390. doi: 10.1161/CIRCINTERVENTIONS.120.010390.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

FRANCE TAVI Registry: Coronary Adverse Events After TAVI

Between 30% and 70% of patients undergoing transcatheter aortic valve implantation (TAVI) have coronary artery disease (CAD). However, the prognostic impact of CAD in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...